Retail expansion by major cannabis brands affects patient access patterns and product availability in clinical cannabis programs. The geographic distribution of dispensaries directly impacts patient compliance and treatment continuity, particularly for mobility-limited patients or those in underserved communities.
STIIIZY, a California-based cannabis brand, has proposed opening a new retail location in San Pablo. This represents continued market expansion by established cannabis companies into new municipal markets. The clinical relevance centers on patient access rather than any specific therapeutic development, as retail availability remains a significant barrier to consistent medical cannabis treatment for many patients.
“Access is medicine — when patients can’t reliably obtain their prescribed cannabis products, treatment fails. Geographic expansion by established retailers can improve continuity of care, but only if they maintain consistent product quality and strain availability.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
